Skip to content

aTyr Pharma ATYR Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
United Therapeutics logo
United TherapeuticsUTHR
20.3%+0.3pp
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-31.3%+19.5pp
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-42.6%-4.6pp
Vor Biopharma logo
Vor BiopharmaVOR
-125.4%+671pp

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

Based on trailing twelve months.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's return on equity?
aTyr Pharma (ATYR) reported return on equity of -105.3% in Q1 2026.
How has aTyr Pharma's return on equity changed year-over-year?
aTyr Pharma's return on equity decreased by 32.5% year-over-year, from -79.5% to -105.3%.
What is the long-term trend for aTyr Pharma's return on equity?
Over 5 years (2020 to 2025), aTyr Pharma's return on equity has grown at a 11.9% compound annual growth rate (CAGR), from -61.4% to -107.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.